Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 7Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 369Pemetrexed 310pembrolizumab 303Cisplatin 244Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28tislelizumab 26cemiplimab 26avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × futuximab × Clear all
NCT02924233 2017-08-28

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Symphogen A/S

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡